January 2, 2025
Sonoran Biosciences has received a Phase 2 SBIR award from the National Institutes of Health for $2.49 million
September 24, 2024
Sonoran Biosciences Announces Issuance of a Second US Patent for Its SB Gel Extended-Release Technology
July 3, 2024
Sonoran Biosciences Reports Publication of Positive Results in a Knee Surgery Model of Postoperative Pain
September 6, 2022
Sonoran Biosciences has received a Phase 1 SBIR award from the National Institutes of Health for $259,613
August 9, 2022
Sonoran Biosciences Reports Publication of Analgesia Results for Postoperative Pain Program
November 16, 2021
Sonoran Biosciences Announces Issuance of US Patent For SB Gel Extended-Release Technology
August 3, 2020
Sonoran Biosciences Announces Qualified Infectious Disease Product (QIDP) Designation Granted by FDA for SBG003 for Surgical Site Infections in Abdominal Surgery
August 1, 2019
Sonoran Biosciences has received a Phase 2B SBIR award from the National Institutes of Health for $2 million
October 24, 2018
Sonoran Biosciences has filed a new patent application on the SB Gel platform
October 24, 2017
Sonoran Biosciences has filed a new provisional patent application on improved formulation and stability of SB Gel platform
August 09, 2016
Sonoran Biosciences has received a Phase 2 SBIR award from the National Institutes of Health for $1.48 million